Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333202 | 0.92 | CYP2C19 (0.50) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| Cpi 613 SCHEMBL13333201 | 0.91 | CYP2C19 (0.59) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| Cpi 613 SCHEMBL1062218 | 0.91 | CYP2C19 (0.59) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| SCHEMBL17973796 | 0.90 | CYP2C19 (0.43) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| SCHEMBL22299081 | 0.90 | CYP2C19 (0.58) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| SCHEMBL17381514 | 0.90 | CYP2C19 (0.58) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| SCHEMBL10307745 | 0.84 | CYP2C19 (0.50) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307804 | 0.83 | CYP2C19 (0.56) | CYP2C19LTA4HPTGER1PTGER4PTGER3 | |
| SCHEMBL20395792 | 0.83 | CYP2C19 (0.63) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307821 | 0.82 | CYP2C19 (0.55) | CYP2C19LTA4HPTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | RAFAEL PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-9839691-B2 | Methods of treating pancreatic and ovarian cancers using compositions containing an ion pair of a lipoic acid derivative | RAFAEL PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170056355-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160220678-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | RAFAEL PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-9320726-B2 | Methods of treating colon, lung, and liver cancers using compositions containing an ion pair of a lipoic acid derivative | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320726-B2 | Methods of treating colon, lung, and liver cancers using compositions containing an ion pair of a lipoic acid derivative | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9150509-B2 | Lipoic acid derivatives | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150509-B2 | Lipoic acid derivatives | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150011633-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20120178812-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| WO-2011050261-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2008131117-A1 | LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008131114-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | ALOX15B, ALOX5, SLC25A21 | CYP2C19 765/4885LTA4H 476/4885PTGER1 924/4885 |
| US-20160220678-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885LTA4H 317/4885PTGER1 1759/4885 |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885LTA4H 317/4885PTGER1 1759/4885 |
| US-20170056355-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | LIPA, LIPC, TTPA | CYP2C19 295/4885LTA4H 69/4885PTGER1 1941/4885 |
| US-20120178812-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | LIPA, LIPC, TTPA | CYP2C19 295/4885LTA4H 69/4885PTGER1 1941/4885 |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | DLD, SLC25A1, PDK2 | CYP2C19 3913/4885LTA4H 738/4885PTGER1 1489/4885 |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885LTA4H 317/4885PTGER1 1759/4885 |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | TTPA, LIPA, LIPC | CYP2C19 273/4885LTA4H 110/4885PTGER1 1623/4885 |
| US-20150011633-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | LIPA, LIPC, TTPA | CYP2C19 295/4885LTA4H 69/4885PTGER1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.